Can a zap of electricity cure long COVID? new trial aims to find out
NCT ID NCT06544395
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a non-invasive device that gently stimulates nerves can help people with long COVID symptoms like muscle pain, breathing issues, and loss of taste or smell. About 104 adults who had COVID-19 and still have symptoms for at least 30 days will receive either the real treatment or a placebo (device turned off) over 5 weeks. Researchers will track changes in symptoms and quality of life up to 11 weeks after starting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- non-invasive neuromodulation therapy (device)
- What this could lead to
- If it works, this could offer a drug-free way to relieve lingering COVID-19 symptoms like muscle pain, breathing trouble, and loss of taste or smell.
- What could go wrong
- This is a small, early-stage trial with no phase designation. The placebo group uses a machine turned off, so results may be influenced by expectation. Long-term benefits are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 104 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients between the ages of 18 and 60. * Patients with a positive diagnosis of COVID-19. * Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases. * Patients who signed the informed consent. Exclusion criteria: * Patients aged before 18 years and after 60 years. * Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases * Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 recurrent are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Gema León Physiotherapy and Rehabilitation Clinic
Córdoba, Andalusia, 14011, Spain